Zevra Therapeutics, Inc. (ZVRA)

Several events have impacted Zevra Therapeutics' stock price, including the FDA approval of MIPLYFFA on September 20, 2024, and JMP Securities initiating coverage with a "Market Outperform" recommendation on September 24, 2024. The company reported full-year 2024 net revenue of $23.6 million and an agreement to sell a Priority Review Voucher (PRV) for $150 million on March 11, 2025. On May 13, 2025, Zevra reported Q1 2025 net revenue of $20.4 million and confirmed the receipt of $148.3 million from the PRV sale. On August 12, 2025, the company reported Q2 2025 net revenue of $25.9 million, but experienced weak OLPRUVA adoption, leading to impairment charges. Insider buying and stock option grants were reported as of October 11, 2025. The share price increased by 36.90% between October 25, 2024, and October 24, 2025, with a 46.6% increase over the past six months.

There is no explicit indication of significant demand seasonality for Zevra Therapeutics' products and services. Demand is typically driven by patient diagnoses and ongoing medical needs rather than seasonal fluctuations.

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited treatment options. The company's portfolio includes clinical-stage pipeline candidates and commercial-stage assets such as MIPLYFFA for Niemann-Pick disease type C, OLPRUVA for urea cycle disorders, AZSTARYS for ADHD, KP1077 for idiopathic hypersomnia and narcolepsy, and Celiprolol for vascular Ehlers-Danlos syndrome.

Zevra Therapeutics is headquartered in Celebration, Florida, United States. The company primarily generates revenue from the United States through its commercial products, MIPLYFFA and OLPRUVA. Zevra is expanding internationally, with revenue from the French Accès Compassionnel program for arimoclomol and a marketing authorization application submitted to the European Medicines Agency.

Zevra Therapeutics rebranded from KemPharm in 2023 to reflect its focus on rare diseases. The FDA approval and rapid uptake of MIPLYFFA positively impacted the company's reputation, while weak OLPRUVA adoption negatively affected the perception of its commercial execution. The acquisition of Acer Therapeutics in November 2023 demonstrated the company's strategy to expand its rare disease offerings.

Zevra Therapeutics has significant institutional ownership, with 237 institutional owners holding 64.43% of the company's shares. Zevra Therapeutics insiders own 22.25%, and retail investors own 13.32%. Major institutional owners include Woodline Partners LP, Adage Capital Partners Gp, L.l.c., BlackRock, Inc., Vanguard Group Inc, Fmr Llc, Rubric Capital Management LP, Nantahala Capital Management, LLC, and Geode Capital Management, Llc. Delaware Street Capital Master Fund LP is the largest individual shareholder, with Samuel J. Braun and Christal M. M. Mickle also being notable individual/insider owners.